glp·helper
glphelper.com/ozempic/north-carolina/goldsboro
GLP-1 receptor agonistFDA-approved December 2017Rx · Subcutaneous injection · Once weekly

Ozempic® providers &
prescriptions in Goldsboro, NC

Verified Ozempic providers in Goldsboro, NC. Checked against the NPI registry, never ranked by who pays us.[7]

average Ozempic weight loss →trial-anchored estimate
city providers
27
as of today
§ 02Provider directory: North Carolina
27 of 27 shown

Find an Ozempic provider in North Carolina.

Every entry is checked against the federal NPI registry. We do not accept payment for placement.

Filter →
Type
Provider
City
Insurance / phone
Browse by North Carolina city · /ozempic/north-carolina/{city}
§ 03Getting Ozempic in Goldsboro
27 providers · Goldsboro, NC

How to get Ozempic in Goldsboro.

27 GLP-1 prescribers and 6 local resource types are on record for Goldsboro, plus 3 nearby towns in the directory.

Prescribers in Goldsboro
27 prescribers
27 GLP-1 prescribers in Goldsboro, most listed as Internal Medicine (12), Family Medicine (11) and Internal Medicine, Endocrinology, Diabetes & Metabolism (2). Any North Carolina-licensed physician, nurse practitioner, or PA can prescribe Ozempic, over video or in person. The nearest towns on record are Wilson (27 providers), Greenville (35 providers) and Rocky Mount (28 providers).
Around the prescription in Goldsboro
6 listed nearby
29 dietitians, 3 nutritionists, 6 gyms, 6 fitness clubs, 6 trainers and 5 physiotherapists are on record near Goldsboro.
Medicaid (weight loss)
Covered
As of April 2026, North Carolina Medicaid covers GLP-1s for weight loss, usually with prior authorization and BMI criteria, on top of the standard diabetes coverage. Employer and private plans vary; coverage is a plan-design choice, not a state rule.

Medicaid status above is for weight-loss use and was compiled April 2026 from KFF and public Medicaid trackers; only 13 states cover it and several are mid-change, so confirm North Carolina’s current Medicaid and plan rules before booking. GLPHelper provides information and provider matching, not medical or coverage advice.

§ 04Medication factsheet
cited · last review 2026.05.19

An injectable medication for adults with type 2 diabetes, and, by indirect effect, for body weight.

Ozempic is the brand name for semaglutide, a once-weekly subcutaneous injection in the GLP-1 receptor agonist class. It mimics a gut hormone that signals satiety to the brain and slows gastric emptying. In randomized trials it lowered HbA1c by 1.4 to 1.8 percentage points and produced a mean weight loss of 4.5 to 6.4 kg at the 1 mg dose.[2][3]

It is FDA-approved for glycemic control in adults with type 2 diabetes mellitus and for reducing the risk of major cardiovascular events in adults with T2D and established cardiovascular disease. The same molecule, marketed by the same manufacturer as Wegovy, is the FDA-approved formulation for chronic weight management.[1]

For the receptor story in plain English, read how does ozempic work.

Rapid weight loss can change the midface. The mechanism people call ozempic face is in the research notes.

At a glanceNDC 0169-4132
Generic name
semaglutide
Drug class
GLP-1 receptor agonist
Manufacturer
Novo Nordisk
FDA approved
December 2017
Approved use
Type 2 diabetes mellitus (adults)
Off-label use
Weight management (Wegovy is the FDA-approved formulation for obesity)
Administration
Subcutaneous injection · Once weekly
Available doses
0.25 mg · 0.5 mg · 1 mg · 2 mg
Half-life
≈ 7 days
Pregnancy
Discontinue ≥ 2 months before planned pregnancy

Community health · CDC

Weight & metabolic health in Goldsboro

Goldsboro, North Carolina has a population of 33,657 people. The adult obesity rate in Goldsboro is an age-adjusted estimate of 43.6%, 9.1 percentage points above the North Carolina state rate of 34.5%. Diagnosed diabetes reaches 15.2% of adults in Goldsboro. Inactivity, meaning no leisure-time physical activity reported in the past month, affects 31.4% of adults in Goldsboro.

of Goldsboro adults have obesity
43.6%
diagnosed diabetes
15.2%
no regular physical activity
31.4%

Age-adjusted estimates for Goldsboro, community figures, not individual risk. CDC PLACES, 2025 release.

Estimate your weight losshair shedding during weight loss
§ 05Support around Ozempic in Goldsboro
6 fitness clubs

The prescription is one part. Here is the rest, in Goldsboro.

Trials of semaglutide paired the drug with diet counseling and regular activity. Every name below is a real listing near Goldsboro, NC, ordered as the registry lists them, never by who pays us.

Fitness clubs and recreation centers

Fitness clubs and recreation centers run classes and pools, an easier start than a weight room.

W A Foster Recreation Center
REC CENTER
4.6 on Google · 186 reviews
1012 S John St
Website
Goldsboro Family YMCA
FITNESS
3.6 on Google · 104 reviews
1105 Parkway Dr
Website
CrossFit Bohica
FITNESS
5.0 on Google · 41 reviews
1208 N Berkeley Blvd
Website
Momentum Fitness
FITNESS
5.0 on Google · 12 reviews
101 Millbrook Village Dr E
Website
Planet Fitness
GYM
4.4 on Google · 652 reviews
201 N Berkeley Blvd
Website
Gold's Gym
GYM
4.0 on Google · 163 reviews
1306 Parkway Dr
Website

Registered dietitians

A registered dietitian builds the food plan around your prescription. Call to ask about GLP-1 nutrition plans and insurance.

Ashleigh Barfield, MS, RD, LDN
RD
Registered dietitian
301 N Herman St
Call 919-731-1000NPI 1275043499
Kali Barley, R.D
RD
Registered dietitian
2600 Us Highway 70 W
Call 919-739-4808NPI 1669809984
Michael Barreras, RDN
RD
Registered dietitian
208 Cox Blvd Ste 102
Call 919-731-6018NPI 1477227254
Artenida Cela, RD/LDN
RD
Registered dietitian
34 Healthpark Way Ste 100
Call 919-585-8850NPI 1174876114
Carissa Christensen
RD
Registered dietitian
1050 Jabara Ave
Call 919-722-0928NPI 1700876596
Ashton Cooper, MS, RD, LDN
RD
Registered dietitian
301 N Herman St
Call 919-731-1222NPI 1326387325
§ 06Clinical evidence
N = 8,416 across SUSTAIN 1 to 7

What the trials actually showed.

We summarize results from the SUSTAIN program, the seven Phase III randomized trials Novo Nordisk submitted to the FDA, and the SUSTAIN-6 cardiovascular outcomes trial. Numbers below are means at the 30-week endpoint, 1 mg weekly dose.

SUSTAIN 1 through 7 compared semaglutide against placebo, sitagliptin, exenatide ER, insulin glargine, and dulaglutide. Semaglutide produced superior HbA1c and body-weight reductions in every active comparator trial.[3]
SUSTAIN endpoint table1 mg / 30 wk
HbA1c reduction
−1.4 to −1.8%
vs. placebo at 30 wk[3]
Weight change
−4.5 to −6.4 kg
mean, 1 mg dose[3]
Major adverse cardiac events
−26%
HR 0.74 vs. placebo[2]
Patients reaching HbA1c <7%
72%
1 mg dose, 30 wk[3]
Effect size varies with baseline characteristics and adherence. Individual response may differ materially.
average Ozempic weight loss →mapped to your starting weight
§ 07Safety & adverse events
from FDA label, sect. 6.1

Most side effects are gastrointestinal and resolve within weeks.

The most common adverse events in SUSTAIN trials were nausea (15 to 20%), diarrhea (8 to 9%), and vomiting (5 to 9%), all dose-dependent and typically transient.[1] Serious events were rare but include pancreatitis, gallbladder disease, and an FDA boxed warning regarding thyroid C-cell tumors based on rodent data.[8]

Boxed warning. Contraindicated in personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN-2).
Effect
Frequency
Severity
Note
Nausea
15 to 20%
mild
Most common; typically dose-dependent and resolves within weeks
Diarrhea
8 to 9%
mild
More frequent during dose escalation
Vomiting
5 to 9%
mild
Reduced by slower titration
Constipation
3 to 7%
mild
Abdominal pain
5 to 7%
moderate
Pancreatitis
<0.3%
serious
Discontinue if confirmed; black-box adjacent
Gallbladder disease
1.5%
serious
Cholelithiasis risk elevated with rapid weight loss
Thyroid C-cell tumors
rodent data
boxed warning
Contraindicated in MTC or MEN-2 history
§ 08Cost & coverage, published, not gated
USD · monthly

Most directories hide the price. We don't.

Cash prices vary roughly 50× between the brand-name retail rate and a manufacturer savings card. The number you actually pay depends on your insurance plan, your diagnosis code, and which pharmacy fills the script. Here are the ranges, plainly.

Data sources: GoodRx national retail survey[6], CMS Part D formulary files[5], Novo Nordisk patient access program.

Cash (no insurance)
$950 to $1,150
per month
National pharmacy average, brand-name[6]
Commercial insurance (covered)
$25 to $250
per month copay
Varies by PBM; T2D indication usually covered
Commercial insurance (off-label / weight)
Typically denied
PA required; majority denied for weight indication
Medicare Part D
$0 to $100
per month
T2D covered; weight loss not covered by law[5]
Manufacturer savings card
as low as $25
per month
Commercial only; eligibility limits apply
Compounded semaglutide
$150 to $400
per month
503A pharmacies; FDA scrutiny ongoing[8]
Updated weekly · last fetch 2026-05-18 04:00 UTCCost methodology →
Find Ozempic providers in North Carolina

NPI-verified Ozempic (semaglutide) prescribers and clinics, never ranked by who pays us.

Ozempic in other states

Find NPI-verified Ozempic (semaglutide) doctors, clinics, and pharmacies in the states we cover, never ranked by who pays us.

Related GLP-1 research
§ 09Frequently asked: Ozempic in North Carolina

The questions people ask before they book.

Answers reviewed by the GLPHelper Medical Team. Citations link to primary sources, never marketing copy.

Yes. Semaglutide is a federally scheduled prescription drug in all 50 states. A licensed prescriber (MD, DO, NP, or PA) must evaluate you before issuing a prescription. No state permits pharmacist-initiated prescribing of GLP-1s.[1]